Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously

Capsules, Oral, (TBD) mg, Q 12 h, Continuously

Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously